Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study
Lupus Sci Med. 2025 May 6;12(1):e001484 doi: 10.1136/lupus-2024-001484
Considering both patient and clinician perspectives on domain importance, and factors influencing domain utility in the specific context of a clinical trial, consensus was achieved to include eight domains of active SLE (alopecia, arthritis, haemolytic anaemia, nephritis, mucosal ulcers, rash, serositis and thrombocytopenia) for defining meaningful treatment response in a novel clinical outcome assessment for SLE clinical trials, in this two-stage modified Delphi study.